mutation class

Gene Rearrangement

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

173 sites for NCT04819100

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

104 sites for NCT04589845

AKT1 Mutation, +39 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +8 more drugs

immunotherapy, +1 more type

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

155 sites for NCT03178552

ALK Alternative Transcription Site, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +2 more drugs

immunotherapy, +1 more type

A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

79 sites for NCT03157128

RET Fusion, +1 more biomarker

Adrenal Gland Pheochromocytoma, +5 more conditions

selpercatinib

targeted therapy

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

185 sites for NCT04194944

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

254 sites for NCT04268550

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

pralsetinib

RET Fusion

Thyroid Gland Carcinoma

Advanced, +1 more state

pralsetinib

targeted therapy

pralsetinib

RET Fusion

Non-Small Cell Lung Carcinoma

Metastatic

pralsetinib

targeted therapy

selpercatinib

RET Fusion

Non-Small Cell Lung Carcinoma

Metastatic

selpercatinib

targeted therapy

selpercatinib

RET Fusion

Thyroid Gland Carcinoma

Advanced, +1 more state

selpercatinib

targeted therapy

cabozantinib

RET Fusion

Non-Small Cell Lung Carcinoma

Advanced, +1 more state

First line, +1 more context

cabozantinib

targeted therapy

pralsetinib

RET Fusion

Thyroid Gland Papillary Carcinoma

Advanced, +2 more states

pralsetinib

targeted therapy